University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Jennifer R. Grandis, MD

Jennifer R. Grandis, MD

American Cancer Society Professor
Professor, Otolaryngology – Head and Neck Surgery, UCSF

Cancer Center Program Memberships

Experimental Therapeutics

Research Summary

I am Professor of Otolaryngology-Head and Neck Surgery and Associate Vice Chancellor for Clinical and Translational Research at UCSF, where I also direct the Clinical and Translational Science Institute (CTSI). My own research efforts are focused on elucidating and targeting key signaling pathways in head and neck cancer. I directed the head and neck cancer program at the University of Pittsburgh Cancer Institute from 1998-2014 and in this capacity facilitated collaborations between clinicians and investigators with an emphasis of developing a robust research infrastructure to support translational cancer studies. I served as PI of the SPORE in Head and Neck Cancer at the University of Pittsburgh from 2002-2014 and now serve as Co-PI of that SPORE in a multi-PI structure. I am a member of the Developmental Therapeutics Program at the HDFCCC and facilitate interactions between the cancer center and the CTSI.

Education

  • Swarthmore College, BA, Biology, 1982
  • Swarthmore College, BA, Art History, 1982
  • University of Pittsburgh, M.D., School of Medicine, 1987
  • University of Pittsburgh, Residency, School of Medicine, Surgery, 1988
  • University of Pittsburgh, Research Fellowship, School of Medicine, Infections Disease, 1992
  • University of Pittsburgh, Residency, School of Medicine, Otolaryngology, 1993

Honors & Awards

  • 1987
    University of Pittsburgh, School of Medicine, Kenneth H. Hinderer Award in Otolaryngology
  • 1987
    University of Pittsburgh, School of Medicine, Leo H. Criep, Award in Medicine,
  • 1986 University of Pittsburgh, Alpha Omega Alpha
  • 1982
    Swarthmore College, Oak Leaf Award
  • 2002
    American Society for Clinical Investigation, Elected Member
  • 2003
    University of Pittsburgh Cancer Institute, Scientific Leadership Award
  • 2005 -
    2014
    Pittsburgh Magazine, Top Doctor
  • 2008 -
    presAmerican Cancer Society, American Cancer Society Clinical Research Professorship
  • 2009
    University of Pittsburgh, Chancellor’s Distinguished Research Award
  • 2009
    MD Anderson Cancer Center, Waun Ki Hong Visiting Professorship
  • 2010
    University of Pittsburgh School of Medicine, Philip Hench Distinguished Alumnus Award
  • 2010
    Association of American Physicians, Elected Member
  • 2011
    University of Pittsburgh, Provost’s Award for Excellence in Mentoring
  • 2012
    The Ochsner Clinic Foundation, Alton Oschner Award Relating Smoking and Disease
  • 2012
    Institute of Medicine (IOM) of The National Academies, Elected Member
  • 2012
    University of Pittsburgh School of Medicine, Distinguished Professor of Otolaryngology
  • 2014
    University of Pittsburgh and Carnegie Mellon University, William E. Brown Outstanding MSTP Mentor Award, Medical Scientist Training Program
  • 2015
    Peggy Wheelock Award for Excellence in Research, Mentoring, and Promotion of Women in Science

Selected Publications

  1. Cui Z, Kang H, Grandis JR, Johnson DE. CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers. Mol Cancer Res. 2020 Sep 03.
    View on PubMed
  2. Bauman JE, Ohr J, Gooding WE, Ferris RL, Duvvuri U, Kim S, Johnson JT, Soloff AC, Wallweber G, Winslow J, Gaither-Davis A, Grandis JR, Stabile LP. Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. Cancers (Basel). 2020 Jun 11; 12(6).
    View on PubMed
  3. Izumi H, Wang Z, Goto Y, Ando T, Wu X, Zhang X, Li H, Johnson DE, Grandis JR, Gutkind JS. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer. . 2020 07; 19(7):1562-1571.
    View on PubMed
  4. Ngan HL, Liu Y, Fong AY, Poon PHY, Yeung CK, Chan SSM, Lau A, Piao W, Li H, Tse JSW, Lo KW, Chan SM, Su YX, Chan JYK, Lau CW, Mills GB, Grandis JR, Lui VWY. MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. Life Sci Alliance. 2020 06; 3(6).
    View on PubMed
  5. Lee MJ, Jin N, Grandis JR, Johnson DE. Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. Biochim Biophys Acta Mol Cell Res. 2020 06; 1867(6):118679.
    View on PubMed
  6. O'Keefe RA, Bhola NE, Lee DS, Johnson DE, Grandis JR. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. PLoS One. 2020; 15(1):e0227261.
    View on PubMed
  7. Lau YK, Ramaiyer M, Johnson DE, Grandis JR. Targeting STAT3 in Cancer with Nucleotide Therapeutics. Cancers (Basel). 2019 10 29; 11(11).
    View on PubMed
  8. Hu L, Li H, Lee ED, Grandis JR, Bauman JE, Johnson DE. Gene targets of sulforaphane in head and neck squamous cell carcinoma. Mol Med Rep. 2019 Dec; 20(6):5335-5344.
    View on PubMed
  9. Cai Y, Yousef A, Grandis JR, Johnson DE. NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer. Adv Biol Regul. 2020 01; 75:100653.
    View on PubMed
  10. Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. Clin Cancer Res. 2019 10 01; 25(19):5752-5758.
    View on PubMed
  11. Meister KS, Godse NR, Khan NI, Hedberg ML, Kemp C, Kulkarni S, Alvarado D, LaVallee T, Kim S, Grandis JR, Duvvuri U. HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma. Sci Rep. 2019 06 24; 9(1):9130.
    View on PubMed
  12. Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, Grandis JR, Johnson DE. ATR inhibition sensitizes HPV- and HPV+ head and neck squamous cell carcinoma to cisplatin. Oral Oncol. 2019 08; 95:35-42.
    View on PubMed
  13. Sola AM, Johnson DE, Grandis JR. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opin Investig Drugs. 2019 04; 28(4):351-363.
    View on PubMed
  14. Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL. Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Res. 2019 Feb 15; 79(4):875.
    View on PubMed
  15. Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. J Exp Med. 2019 02 04; 216(2):419-427.
    View on PubMed
  16. Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, Grandis JR, Yarbrough WG, Burtness B, Anderson KS, Townsend JP. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene. 2019 05; 38(18):3475-3487.
    View on PubMed
  17. Lee YS, Johnson DE, Grandis JR. An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs. 2018 12; 23(4):283-299.
    View on PubMed
  18. Zhang L, Li Z, Liu Y, Xu S, Tandon M, Appelboom B, LaValle CR, Chiosea SI, Wang L, Sen M, Lui VWY, Grandis JR, Wang QJ. Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. BMC Cancer. 2018 Nov 12; 18(1):1107.
    View on PubMed
  19. Frazier NM, Brand T, Gordan JD, Grandis J, Jura N. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene. 2019 03; 38(11):1936-1950.
    View on PubMed
  20. Bauman JE, Duvvuri U, Thomas S, Gooding WE, Clump DA, Karlovits B, Wehbe A, Miller FR, Kim S, Sen M, Heron DE, Grandis JR, Argiris A. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. Cancer. 2018 10 01; 124(19):3881-3889.
    View on PubMed

Go to UCSF Profiles, powered by CTSI